Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo

PHASE3CompletedINTERVENTIONAL
Enrollment

1,023

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

June 28, 2019

Study Completion Date

July 3, 2019

Conditions
Ebola Virus Disease
Interventions
BIOLOGICAL

Ad26.ZEBOV

Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles.

BIOLOGICAL

MVA-BN-Filo

MVA-BN-Filo- is a non-replicating vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit (Inf. U.).

BIOLOGICAL

MenACWY

MenACWY is a WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.

BIOLOGICAL

Placebo

0.9% saline for injection.

Trial Locations (1)

Unknown

Freetown

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

Ministry of Health and Sanitation, Sierra Leone

OTHER_GOV

collaborator

University of Sierra Leone

OTHER

collaborator

University of Oxford

OTHER

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

Grameen Foundation

OTHER

collaborator

World Vision, Ireland

OTHER

lead

Janssen Vaccines & Prevention B.V.

INDUSTRY